Although many chemotherapeutic agents and combinations are available, the overall prognosis of patients with advanced gastrointestinal cancer remains poor.ĭistinct molecular pathways have been identified in each tumor type. Gastrointestinal cancers are among the leading causes of cancer morbidity and mortality worldwide. Keywords: Biomarker gastrointestinal cancer RAS human epidermal growth factor receptor 2 (HER2) BRCA
#Prognostic vs predictive update
This review provides an update of the main biomarkers currently used in colorectal, gastric and pancreatic cancers, and reviews those that are being developed. In pancreatic cancer, BRCA is a tool used to differentiate patients who are likely to respond to platinum-based combination therapies and to benefit from poly (ADP-ribose) polymerase (PARP) inhibitors. These include rat sarcoma-2 virus ( RAS) which is used to identify colorectal cancer (CRC) patients who will not respond to anti-epidermal growth factor receptor (EGFR) agents, while in gastric cancer, anti-human epidermal growth factor receptor 2 (HER2) therapy has been shown to only be active in HER2-positive patients. Several biomarkers are currently widely employed in gastrointestinal cancers. Prognostic biomarkers enable identification of patients with a more aggressive tumor evolution, while predictive biomarkers permit the identification of patients with a higher probability of responding or not to a specific treatment. In gastrointestinal cancer, there is increasing interest in their development and validation according to specific tumor type.
0 kommentar(er)
